Biosketch / Results /

Andrew Talal

Adjunct Associate Professor, Department of Medicine
Medicine

Contact Info

212/745-4495
Andrew.Talal@nyumc.org


Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis
Dimova, Rositsa B; Zeremski, Marija; Jacobson, Ira M; Hagan, Holly; Des Jarlais, Don C; Talal, Andrew H
2013-03-27; 1058-4838,Clinical infectious diseases - id: 249362, year: 2013 Journal Article

Determinants of treatment completion and efficacy in drug users assessed by meta-analysis
Dimova, R B; Zeremski, M; Jacobson, I M; Hagan, H; Des, Jarlais D C; Talal, A
2013-01-02; 0270-9139,Hepatology - id: 207622, year: 2012

Absolute and relative contraindications to pegylatedinterferon (PEG-IFN) or ribavirin (RBV) in the US general patient population with chronic Hepatitis C (HCV): Results from US Database of Over 45,000 Patients
Talal, A; LaFleur, J; Hoop, R S; Pandya, P K; Martin, P; Jacobson, I M; Han, J; Korner, E
2012-12-29; 0270-9139,Hepatology - id: 206142, year: 2012

Hepatitis C virus infection in USA: an estimate of true prevalence
Chak, Eric; Talal, Andrew H; Sherman, Kenneth E; Schiff, Eugene R; Saab, Sammy
2012-02-05; 1478-3231,Liver international - id: 143762, year: 2011

Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
Charles, Edgar D; Brunetti, Claudia; Marukian, Svetlana; Ritola, Kimberly D; Talal, Andrew H; Marks, Kristen; Jacobson, Ira M; Rice, Charles M; Dustin, Lynn B
2012-02-05; 1528-0020,Blood - id: 143763, year: 2011